Diffuse Large B Cell Lymphoma Clinical Trials in Tianjin, Tianjin Municipality
8 recruitingTianjin, Tianjin Municipality, China
Showing 1–8 of 8 trials
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Hoffmann-La Roche300 enrolled12 locationsNCT07200375
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 2
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Diffuse Large B Cell LymphomaPeripheral T Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China115 enrolled1 locationNCT06244368
Recruiting
Phase 1Phase 2
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China108 enrolled1 locationNCT06594640
Recruiting
Phase 2
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Tianjin Medical University Cancer Institute and Hospital22 enrolled1 locationNCT06570447